Consensus Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 14/02/2026 am IST			5-day change	1st Jan Change
803.17 ^USD	+2.49%		+2.25%	+4.06%

13/02	HSBC Adjusts Price Target on Regeneron Pharmaceuticals to $990 From $985, Maintains Buy Rating	MT
12/02	Regeneron Pharmaceuticals Insider Sold Shares Worth $1,585,058, According to a Recent SEC Filing	MT

Evolution of the Average Target: Regeneron Pharmaceuticals, Inc.

Evolution of the Target Price: Regeneron Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Regeneron Pharmaceuticals, Inc.

6492f6c046b3415bea9614793.mLdn_4k1w1DwwBnIRaAK98rSX7meKc7Fr4crBs90qQ8.7cMQjdNsphqA-GiuctVLgp6ZbP-rHYG3ne5BYIwAn1z0hFW-4Fm6Z8WQcg~5b309ed9eb32557487abbf22809f63ac

Analysts' recommendations: Regeneron Pharmaceuticals, Inc.

13/02	HSBC Adjusts Price Target on Regeneron Pharmaceuticals to $990 From $985, Maintains Buy Rating	MT
10/02	Regeneron Pipeline Progress Continues but Near-Term Visibility Remains Limited, RBC Says	MT
09/02	Rothschild & Co Redburn Adjusts Price Target on Regeneron Pharmaceuticals to $950 From $940, Maintains Buy Rating	MT
02/02	Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $800 From $740, Maintains Overweight Rating	MT
02/02	JPMorgan Adjusts Price Target on Regeneron Pharmaceuticals to $950 From $850, Maintains Overweight Rating	MT
28/01	Wolfe Adjusts Price Target on Regeneron Pharmaceuticals to $900 From $800, Maintains Outperform Rating	MT
27/01	Bernstein Adjusts PT on Regeneron Pharmaceuticals to $916 From $911, Maintains Outperform Rating	MT
22/01	Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals to $875 From $750, Maintains Outperform Rating	MT
13/01	Raymond James Adjusts PT on Regeneron Pharmaceuticals to $820 From $800, Keeps Outperform Rating	MT
08/01	RBC Raises Price Target on Regeneron Pharmaceuticals to $766 From $708, Keeps Sector Perform Rating	MT
07/01	BofA Securities Upgrades Regeneron Pharmaceuticals to Buy From Underperform, Raises Price Target to $860 From $627	MT
19/12	Goldman Sachs Adjusts PT on Regeneron Pharmaceuticals to $807 From $788, Maintains Buy Rating	MT
17/12	Leerink Partners Adjusts Regeneron Pharmaceuticals PT to $873 From $710, Maintains Outperform Rating	MT
04/12	Analyst recommendations: Gitlab, Meta, PayPal, Salesforce, Dollar Tree…
04/12	Regeneron Shares Fall After Morgan Stanley Downgrade	MT
03/12	Regeneron Shares Now Reflect Valuation as Pipeline Visibility Becomes Key, Morgan Stanley Says	MT
03/12	Morgan Stanley Downgrades Regeneron Pharmaceuticals to Equalweight From Overweight, PT is $767	MT
03/12	Analyst recommendations: Applovin, Garmin, Lyft, Uber, Netflix…
24/11	HSBC Initiates Regeneron Pharmaceuticals at Buy With $890 Price Target	MT
20/11	Wells Fargo Adjusts PT on Regeneron Pharmaceuticals to $700 From $615, Maintains Equalweight Rating	MT
07/11	UBS Adjusts Price Target on Regeneron Pharmaceuticals to $660 From $595, Maintains Neutral Rating	MT
07/11	Regeneron, Sanofi Say Dupixent for Allergic Fungal Rhinosinusitis Met Primary Endpoint in Phase 3 Study	MT
07/11	Sanofi, Regeneron's Dupixent Hits Key Goals in Late-Stage Fungal Allergy Trial	DJ
31/25/31	Rothschild & Co Redburn Adjusts Price Target on Regeneron Pharmaceuticals to $910 From $900	MT
29/25/29	RBC Raises Price Target on Regeneron Pharmaceuticals to $708 From $704, Keeps Sector Perform Rating	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

803.17USD

Average target price

868.04USD

Spread / Average Target

+8.08%

High Price Target

1,057.00USD

Spread / Highest target

+31.60%

Low Price Target

730.00USD

Spread / Lowest Target

-9.11%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

HSBC
Rothschild & Co Redburn
Guggenheim
Cantor Fitzgerald
JPMorgan Chase
Bernstein
Oppenheimer
TD Cowen
Wolfe Research
Evercore ISI
RBC Capital Markets
Jefferies & Co.
Raymond James
Goldman Sachs
BofA Securities
Leerink Partners
Morgan Stanley
Wells Fargo Securities
BMO Capital
Canaccord Genuity
Scotiabank
UBS
Citigroup
Baird
DBS Bank
Truist Securities
Argus
Piper Sandler
Deutsche Bank Securities
Barclays
WestPark Capital
SVB Securities LLC
EF Hutton
Cowen
Benchmark Capital
HC Wainwright
SVB Leerink
Credit Suisse